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ABSTRACT 
 
 Atopic dermatitis is a type of eczema characterized by chronic inflammation of 
the skin, affecting millions of people worldwide. Resveratrol, a naturally occurring 
stilbenoid, is widely believed to exhibit beneficial effects on a host of chronic diseases. 
Although some previous studies have aimed to evaluate the effects of resveratrol on the 
pathogenesis of atopic dermatitis, this relationship remains ill-defined. We have 
previously established that mast cell activation, remodeling, and cellular infiltration in the 
hypodermis all begin prior to the IgE-mediated immune response in an atopic dermatitis 
mouse model, and that this early pathogenesis is directly related to an increase in local 
levels of sphingosine-1-phosphate. We have found novel evidence that treatment with 
transdermal resveratrol attenuates mast cell activation, perivascular cell infiltration, 
thickening of the epidermis, and inflammatory chemokines relevant to early-phase atopic 
dermatitis. We are currently evaluating the effect of resveratrol on local levels of 
sphingosine-1-phosphate and the activity of sphingosine kinase 1, the major enzyme 
responsible for its production. The results we have obtained thus far support our 
hypothesis that resveratrol can attenuate the development of atopic dermatitis, enabling 
future investigation of its efficacy as a treatment for the disease. We also intend to use 
these results as a gauge to evaluate the effects of other related compounds on the 
development of atopic dermatitis. 
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INTRODUCTION 
 
Resveratrol (RSV) is a naturally occurring stilbenoid most famously found in the 
skin of grapes. It is widely believed to have a vast array of anti-carcinogenic, anti-
inflammatory, and antioxidative protective effects.1-3 RSV is thought to be responsible 
for the “French paradox” which is characterized by lower incidence of cardiovascular 
diseases with red wine consumption, regardless of diets which are typically high in fat.1 
RSV has been shown to modulate different cellular processes including NAD+ 
metabolism via sirtuin 1 (SIRT-1) and poly ADP-ribose polymerase 1 (PARP-1) 
pathways, carcinogenesis through the inactivation of cyclooxygenase (COX) proteins, 
and the phosphorylation of sphingosine by sphingosine kinase 1 (SphK1).2,4-7 Although 
these mechanisms have been subject to extensive research over the last two decades, 
more recent studies have found conflicting evidence surrounding the efficacy of RSV as a 
treatment in various disease models.8 One such conflict has arisen from several studies 
conducted to examine RSV’s effects on modulating sphingosine-1-phosphate (S1P), a 
sphingolipid metabolite with a role in initiating inflammatory responses in mast cells 
(MC).5,7,9-11 We suggest this can be explained by variations in experimental design such 
as routes of administration, dosing, vehicles, specific disease models, and genetic 
differences in cell-lines and mice used.12-14 We previously established that S1P is an early 
modulator of IgE-independent MC activation and skin remodeling in mice, after inducing 
atopic dermatitis (AD) with ovalbumin (OVA).9 We used a similar experimental design 
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for this study to determine the effect of RSV on S1P production and other pre-
symptomatic signs of AD pathogenesis.   
Multiple studies have shown that RSV can attenuate sphingosine kinase 1 
(SphK1)-mediated phosphorylation of sphingosine to produce S1P, but none suggested a 
specific mechanism of action.5,7 We hypothesize that RSV prevents translocation of 
SphK1 from the cytoplasm to the cell membrane, which is required for its activation. We 
propose that this occurs via direct acetylation of SphK1 by RSV in the cytoplasm, based 
on molecular research done by Dr. Mathew.6 We anticipate that our pending results will 
demonstrate inhibition of OVA-induced local skin S1P elevation after transdermal 
application of RSV, preventing the subsequent changes we have previously characterized 
during early-phase AD, thus averting progression to disease.9 
As suggested by previous studies, the low bioavailability of RSV in vivo may 
hinder its delivery in adequate concentrations, limiting its beneficial effects.12-14 
However, other research has shown that delivery of higher RSV concentrations can have 
adverse pro-inflammatory consequences.10,11 We have conducted experiments with two 
different and physiologically relevant concentrations of topical RSV, and though related 
research is scarce, one study suggests these doses may circumvent both of these 
limitations.2 
In addition to providing compelling evidence to support proof of concept, this 
pilot study has established a standard model so that the results of subsequent research can 
be accurately compared. In the future, we plan to observe the effect of RSV on the 
development of AD in the presence of either of two demonstrated cofactors: nicotinamide 
(NAM) and nicotinamide riboside (NR).6 We also plan to evaluate another compound 
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closely related to RSV named pterostilbene (PTE). PTE research is very limited, but 
some studies have suggested that it may have similar effects with higher bioavailability 
than RSV.14-16 
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CHAPTER 1. METHODS 
1.1. Atopic Dermatitis Model 
 
For all experimental groups in this study, we used a well-established AD mouse 
model shown to bare similarity to the pathogenesis of AD in humans.9,17 The methods 
established by our previous study were adapted to evaluate the development of AD in 8-
12 week female wild-type C57Bl/6J mice. Six mice were assigned to each of our four 
experimental groups using a simple randomization technique as previously reported (see 
Table 1.1 for group designations).9  
On Day 1, initial treatment solutions were prepared. First, RSV was dissolved in 
100% ethanol (ETOH) to achieve its maximum soluble concentration of 50 mg/mL. This 
solution was then diluted with 0.9% saline to obtain 2.5 mg RSV/mL 5% ETOH. To 
obtain final solutions for RSV treated groups, this was either further diluted with 0.9% 
saline or combined with OVA in 0.9% saline. For vehicle control groups, 5% ETOH was 
either further diluted with 0.9% saline or combined with OVA in 0.9% saline. All 
treatment solutions are shown in Table 1.1.  
ETOH was used as a vehicle because physiologically relevant concentrations of 
RSV are insoluble in inorganic solvents such as saline.2  By first dissolving RSV in 
ETOH, we were able to maximize its stability and solubility.14,18 Previous research has 
suggested that membrane permeability to trans-RSV is significantly higher than to cis-
RSV, and that the trans- conformation is only stable once diluted to lower 
concentrations.6,13 
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Table 1.1. Experimental Group Designations. 
 
Group Day 1 Treatment Days 2-6 Treatment 
Saline and 
Vehicle (SV) 
0.05% ETOH 
 
0.05% ETOH 
OVA and 
Vehicle (OV) 
100 µg OVA in 0.05% ETOH 
Saline and RSV 
(SR) 
2.5 µg RSV in 0.05% ETOH 
2.5 µg RSV in  
0.05% ETOH OVA and RSV 
(OR) 
100 µg OVA + 2.5 µg RSV in 
0.05% ETOH 
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For the application of Day 1 treatments, the upper-back areas of mice in each 
group were shaved then tape-stripped three times. Next, 100 µL of designated treatment 
solutions were pipetted onto 1 cm by 1 cm square gauze patches. The patches were then 
applied to the shaved and tape-stripped area of each mouse. A half cm section of sterile 
flexible tubing was then placed over the patch with one end over the center of the patch 
and the other extending slightly past its caudal border. The tube and patch were then 
secured with a Tegaderm transparent dressing so that the patch was completely covered, 
and the caudal end of the tubing was flush with the edge of the Tegaderm. To ensure that 
the patch and dressing remained in place, an adhesive bandage was applied over the 
dressing and 1” of transparent tape was applied to the ends of the bandage.9 Shaving, 
tape-stripping, and patching all occurred on Day 1 of the study.  
On Days 2-6, all mice received the same treatments without OVA. Treatments 
given on Days 2-6 are listed in Table 1.1. To apply these daily treatments, Day 1 patches, 
taped bandages, and Tegaderm dressings were left in place to prevent unintended trauma 
to the skin. 100 µL of the assigned treatment solution was pipetted through the flexible 
tubing onto the patch. 
On Day 7, mice were euthanized and the patches were removed. A 1 cm by 1 cm 
skin sample was collected from the treated area and was then cut laterally into four equal 
strips for histological, mRNA, and lipidomic analyses.9 All animal procedures were 
performed in accordance with University of South Carolina Institutional Animal Care and 
Use Committee approval and all methods used adhere to relevant guidelines and 
regulations. 
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1.2. Histology and Microscopy 
 
 Skin samples were fixed in 4% fresh paraformaldehyde, paraffin embedded, 
sectioned, and mounted on microscopy slides by the University of South Carolina School 
of Medicine’s Instrumentation Resource Facility. One slide from each sample was then 
stained with hematoxylin and eosin (H&E) for measurement of skin layer thickness and 
determination of cellular infiltration, and another was stained with methylene blue (MB) 
for MC quantification and MC activation status. 
 H&E slides were stained by the University of South Carolina School of 
Medicine’s Instrumentation Resource Facility. Tagged image file format (TIFF) images 
of these slides were obtained using a Nikon E-600 microscope with Micropublisher 
camera and software at 10x magnification. Cellular infiltration of the hypodermis was 
quantified using MetaMorph 6.1 software and previously reported morphometric 
parameters.9 Skin layer thickness was calculated using the same software and a 
morphometric measurement technique recently adapted by our lab for this purpose.21 The 
investigators who performed this analysis and all subsequent quantifications were single-
blinded to slide group designations. 
For MB staining, slides were prepared by deparaffinization and rehydration. 
Slides were then placed in 0.05% MB for five seconds, rinsed with water, dehydrated in 
100% ETOH, and mounted under coverslips with cytoseal 60.9,19 These sections were 
then imaged using a Nikon E-600 microscope with Micropublisher camera and software 
to obtain TIFF images at 40x magnification. These images were analyzed with 
MetaMorph 6.1 software to quantify MCs and detect MC degranulation using 
morphometric parameters previously published by our lab.9,20  
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1.3. Morphometric Measurement of Skin Remodeling 
 The epidermal, dermal, and hypodermal thickness of each H&E stained sample 
was measured using a morphometric measurement technique recently adapted by our 
lab.21 Three to six images were obtained per animal at 10x magnification, then three 
regions of interest (ROI) were randomly selected for each skin layer per image. 9,20 
MetaMorph 6.1 software was used to trace the perimeter of the target skin layer in each 
ROI. The software provided measurements for the traced area (TA) and its perimeter 
(PR). This TA was treated as an irregular two-dimensional fiber and the equation below 
was used to calculate the average thickness, or breadth, of each fiber.21  
Fiber Breadth (FB) = ¼ [PR - (PR2 – 16TA)1/2] 
FB measurements were compiled to determine the average thickness of the 
epidermis, dermis, and hypodermis for each experimental group. This method is depicted 
in Figure 1.1. 
1.4. Computer Assisted Quantification of Hypodermal Cellular Infiltration 
To quantify hypodermal cellular infiltration, we used an imaging method 
previously developed and published by our lab.9,20 At least 10 images per animal were 
collected from H&E stained slides and analyzed using MetaMorph 6.1 software. The 
distinct blue color of hematoxylin-stained nuclei was identified using the hue, saturation, 
and intensity (HSI) color model through a process called thresholding.20 To eliminate 
background, areas that met this color threshold were further analyzed using 
morphometric parameters to exclude any which were not consistent with previously 
defined size and shape characteristics of nuclei.9,20 The software analyzed images using a 
circular ROI with a fixed diameter (75 µm) which was moved to survey the entire  
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Figure 1.1. Morphometric Measurement of Skin Layer Thickness.  
 
[A] is an image obtained from an H&E stained slide at 10x magnification. The portion of 
the image outlined in white was selected as an ROI for measurement of the epidermis. 
[B] represents the tracing and isolation of the epidermis from the ROI depicted in [A] to 
produce an irregular fiber using MetaMorph software. The software produced values to 
quantify the TA (orange) in µm2 and the PR (blue) in µm of the fiber. This representation 
is enlarged for figure clarity.  
[C] displays the equation used to calculate the FB of the fiber shown in [B]. For our 
purposes, this equation essentially converts the irregular fiber [B] into a rectangle [D] 
while preserving original length to width ratio.  
[D] shows that the FB (purple), or width of the final object represents the average 
thickness of the epidermis. This method was used to calculate average thickness values 
for all skin layers.
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hypodermis in each image. The software then quantified the number of nuclei present in 
each ROI and the average number of nuclei per ROI was calculated by group.9 
1.5. In situ Determination of Mast Cell Degranulation 
Our lab has previously shown that morphometric parameters can be used to 
describe the cytoplasm of MCs and define MC activation status.20 For this analysis, 15 
adjacent images of the dermis and hypodermis were recorded as TIFF files from each MB 
stained slide at 40x magnification. MCs in each image were then identified as individual 
ROI using the HSI color model thresholding routine of MetaMorph 6.1.20 HSI values 
were set to isolate the unique cytoplasmic blue/purple color of MB stained MCs. The 
software’s integrated morphometry routine was then used to measure the area and 
integrated optical density (IOD) of each thresholded ROI.20 IOD values represent the 
total amount of material present in the ROI. The IOD of each ROI was then divided by its 
area and the resulting values were used to identify whether MCs were intact or 
degranulated, as previously reported.9,20 The average number of intact MCs, degranulated 
MCs, and total MCs present in each experimental group were then calculated, analyzed 
for significance, and compared.9 
1.6. Quantitative Reverse Transcription Polymerase Chain Reaction Assay 
 
 One strip from each skin sample was designated for analysis by quantitative 
reverse transcription polymerase chain reaction assay (qRT-PCR). These stripss were 
snap-frozen immediately after collection and stored at -80°C until RNA extraction. Total 
RNA was isolated from each sample with the miRNeasy kit from Qiagen using the 
manufacturer’s protocol. The Bioline cDNA synthesis kit and protocol were used to 
reverse transcribe cDNA from the isolated RNA. QPCR was performed using the Bioline 
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SYBR No-ROX kit with Bio-Rad CFX Connect equipment and software. We analyzed 
target gene mRNA expression for chemokines CCL2, CCL3 and CCL5, as well as 
FcƐRIα and SphK1, relative to reference genes ß-2-microglobulin (B2M) and ß-actin 
(BA). GAPDH was considered as a reference gene but was excluded from data analysis 
because its expression between samples was less consistent than B2M and BA. All 
primer sequences are listed in Table 1.2. QPCR conditions were set to the following, as 
previously reported: 95°C for 10 minutes during the initial step, followed by 40 repeating 
cycles of 95°C for 10 seconds, annealing at 55°C for 20 seconds, and extension at 72°C 
for 15 seconds.9,22 All reactions were performed in duplicate and repeated once. Data was 
normalized to both reference genes independently and fold-change was determined based 
on vehicle-control values. A total of eight fold-change values were obtained per animal 
(48 per experimental group) and outliers were excluded using GraphPad Prism 7.0 
software. This software was then used to calculate average fold-change and standard 
error of the mean (SEM) by group. 
1.7. Statistics 
 For all quantifications, outliers were excluded using GraphPad Prism 7.0 
software. This software was then used to perform a one-way analysis of variance 
(ANOVA) with multiple comparisons to identify statistically significant differences   
between groups for all quantifications. Differences were considered significant for 
probability values (P) less than 0.05. GraphPad Prism 7.0 software was used to create all 
bar graphs. All treatment group results were compared against the SV (vehicle control) 
group since we have not yet included a true negative control group in this study. All qRT-  
12 
 
Table 1.2. qRT-PCR Primer Sequences. 
Gene 
Forward (F) 
Reverse (R) 
5’                    Primer Sequence                    3’ 
B2M 
F CCGAACATACTGAACTGCTACGTAA 
R CCCGTTCTTCAGCATTTGGA 
BA 
F GACGGCCAGGTCATCACTATTG 
R AGGAAGGCTGGAAAAGAGCC 
CCL2 
F CACTCACCTGCTGCTACTCA 
R GCTTGGTGACAAAAACTACAGC 
CCL3 
F GCCATATGGAGCTGACACCC 
R TAGTCAGGAAAATGACACCTGGC 
CCL5 
F TGCCCTCACCATCATCCTCACT 
R GGCGGTTCCTTCGAGTGACA 
FcƐRIα 
F ATTGTGAGTGCCACCGTTCA 
R GCAGCCAATCTTGCGTTACA 
SphK1 
F CGTGGACCTCGAGAGTGAGAA 
R AGGCTTGCTAGGCGAAAGAAG 
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PCR analyses were performed in duplicate and each experimental group consisted of 6 
mice treated in two independent trials. Data collection is not yet complete for some 
histological analyses and all variations in sample size are clearly reported. 
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CHAPTER 2. RESULTS & DISCUSSION 
2.1. Resveratrol Attenuates Remodeling of the Epidermis During Early-Phase 
Atopic Dermatitis 
 
Consistent with our previous work with this murine AD model, we found 
significant thickening of the epidermis and dermis one week after a single exposure to 
OVA in the group that did not receive treatment with RSV (OV) compared to the vehicle 
control group (SV).9 As shown in Figure 2.1A, average thickening of the epidermis was 
significantly reduced in the group that was exposed to OVA and treated daily with RSV 
(OR) compared to the OV group. This finding suggests that RSV prevents remodeling of 
the epidermis during the development of AD. 
We have not seen evidence suggesting that RSV has the same ameliorative effect 
on thickening of the dermis during early-phase AD (Figure 2.1B). However, this may be 
explained by the fact that we have analyzed six images per animal for measurement of 
the epidermis, but only three images per animal for the dermis. The cause of this anomaly 
is not likely to be an inability of RSV to reach the dermis because cellular infiltration of 
the hypodermis was significantly attenuated after RSV treatment.  
Consistent with our previously reported findings, we did not observe any 
significant thickening of the hypodermis one week after exposure to OVA (Figure 2.1C).9 
Although we did observe significantly increased cellular infiltration in the hypodermis, it 
does not seem to cause any significant thickening of this skin layer at this early stage of 
AD pathogenesis.9 While skin layer thickness is an important indicator of AD, cellular 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Skin Layer Thickness.  
 
[A] RSV attenuated OVA-induced thickening of the epidermis. N=3, 6 images per 
animal, 3 ROI per image. OV>OR, P<0.001. OV>SV, P=0.025. OV>SR, P=0.014. 
OR=SV, P=0.266. SR=SV, P=0.387. SR=OR, P=0.175.  
[B] RSV had no significant effect on OVA-induced thickening of the dermis. N=3, 3 
images per animal, 3 ROI per image. OV=OR, P=0.615. OV>SV, P=0.040. OV>SR, 
P=0.007. OR=SV, P=0.484. SR=SV, P=0.930. SR=OR, P=0.186.  
[C] Neither RSV nor OVA exposure had a significant effect on thickening of the 
hypodermis. N=3, 3 images per animal, 3 ROI per image. OV=OR, P=0.859. OV=SV, 
P=0.939. OV=SR, P=0.462. OR=SV, P=0.527. SR=SV, P=0.811. SR=OR, P=0.119. 
 
A 
B C 
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infiltration of the hypodermis likely begins before thickening of any skin layer can be 
detected.  
2.2. Hypodermal Cellular Infiltration is Reduced by Treatment with Resveratrol 
 Using morphometric parameters we have previously defined, we were able to 
quantify cellular infiltration of the entire area of the hypodermis mounted on each H&E 
stained slide.9,20 The number of nuclei identified in each ROI were compiled according to 
experimental group designation and group averages were compared. A separate 
quantification of the number of nuclei present in each ROI which contained blood vessels 
(BV) was also performed and data from both quantifications of hypodermal cellular 
infiltration is displayed in Figure 2.2.  
As we observed previously, both whole hypodermal and perivascular cellular 
infiltration were significantly increased one week after a single exposure to OVA.9 The 
magnitude of this OVA-induced cellular infiltration was significantly decreased after 
daily treatment with RSV, both in the whole hypodermis and near hypodermal blood 
vessels specifically. These findings indicate that RSV can prevent the development of 
AD by reducing the recruitment of cells likely to contribute to early inflammation and 
tissue remodeling. Although these significant increases in hypodermal cellular infiltration 
for OVA exposed groups is significant, hypodermal thickening may not be observed until 
longer-term effects of this infiltration occur. 
2.3. Mast Cell Activation is Attenuated by Resveratrol 
We used our previously described morphometric method to determine the average 
total number of MCs, intact MCs, and degranulated (or activated) MCs per mm2 of skin 
tissue for each treatment group. As shown in Figure 2.3A, we did not observe any  
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Hypodermal Infiltration.  
 
[A] RSV significantly decreased OVA-induced cellular infiltration in the whole 
hypodermis. N=6, 10 images per animal, 10 ROI per image, 600 ROI per group. 
OV>OR, P<0.0001. OV>SV, P<0.0001. OV>SR, P<0.0001. OR>SV, P<0.0001. SR=SV, 
P=0.0713. OR>SR, P<0.0001.  
[B] RSV significantly decreased OVA-induced cellular infiltration around BV in the 
hypodermis. N=6, 10 images per animal, only ROI from [A] containing BV included, 
225-255 ROI per group. OV>OR, P<0.0001. OV>SV, P<0.0001. OV>SR, P<0.0001. 
OR>SV, P<0.0001. SR=SV, P=0.0804. OR>SR, P<0.0001.
A B 
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Figure 2.3. Activity of Mast Cells and Sphingosine Kinase 1.  
 
[A] Neither OVA exposure nor treatment with RSV had a significant effect on the mean 
number of all MCs. N=3, 15 images per animal. OV=OR, P=0.281. OV=SV, P=0.342. 
OV=SR, P=0.145. OR=SV, P=0.561. SR=SV, P=0.263. OR=SR, P=0.344. 
[B] RSV prevented OVA-induced MC degranulation. N=3, 15 images per animal. 
OV>OR, P=0.008. OV>SV, P=0.033. OV=SR, P=0.251. OR=SV, P=0.875. SR=SV, 
P=0.734. OR=SR, P=0.371.  
[C] RSV significantly decreased OVA-induced upregulation of FcƐRIα mRNA. N=6, 8 
fold-change values calculated per animal, 48 fold-change values per group. OV>OR, 
P=0.0355. OV>SV, P<0.0001. OV>SR, P<0.0001. OR>SV, P<0.0001. SR=SV, 
P=0.1098. OR>SR, P=0.0009.  
[D] Neither OVA exposure nor treatment with RSV had a significant effect on SphK1 
mRNA expression. N=6, 8 fold-change values calculated per animal, 48 fold-change 
values per group. OV=OR, P=0.5364. OV=SV, P=0.1621. OV=SR, P=0.2709. OR<SV, 
P=0.0041. SR=SV, P=0.9929. OR<SR, P=0.0100.  
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significant differences in the average number of MCs per mm2 between groups. However, 
Figure 2.3B demonstrates significantly increased MC degranulation one week after 
exposure to OVA and that this increase in degranulation was attenuated after RSV 
treatment. 
As shown in Figure 2.3C, FcƐRIα mRNA expression was significantly increased 
one week after OVA exposure and this increase was ameliorated after treatment with 
RSV. FcƐRIα is the alpha chain of the high affinity IgE receptor. FcƐRIα expression in the 
skin is effectively exclusive to MCs and we have previously shown that its relative 
mRNA expression correlates to the local abundance of MCs.9,24 It is possible that RSV 
decreases expression of FcƐRIα by MCs, making them less susceptible to IgE-mediated 
activation. However, further work is needed to reconcile the discrepancies between this 
data and the results of our histological quantification of MCs.  
Figure 2.3D shows that we found no significant differences in SphK1 mRNA 
expression between groups. This result neither supports nor weakens our hypothesis that 
RSV reduces the activity of SphK1. Since we suggest RSV works by preventing the 
translocation of SphK1 to the cell membrane to reach its substrate, its mRNA expression 
may not be affected. 
2.4. Treatment with Resveratrol Decreases mRNA Expression of Inflammatory 
Chemokines 
 
We have previously shown that CCL2, CCL3 and CCL5 are significant 
contributors to allergic airway and AD skin inflammation.9,24 Based on our previous 
research, we know that OVA exposure promotes the expression of these chemokines.9 
The results of our current work are consistent with our previous findings, except that we 
found no significant increase in CCL3 mRNA expression after OVA exposure. However, 
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this previously reported increase was significantly less than the increases observed in 
CCL2 and CCL5 mRNA. In support of our hypothesis, we have found that mRNA 
expression for both CCL2 and CCL5 were significantly decreased in the OVA exposed 
group that was treated with RSV, compared to the OVA exposed group that did not 
receive treatment. This is consistent with the RSV-mediated decrease in hypodermal 
cellular infiltration we observed because these chemokines are responsible for immune 
cell recruitment. This data is displayed in Figure 2.4. 
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Figure 2.4. Chemokine mRNA Expression. 
 
[A] RSV prevented OVA-induced upregulation of CCL2 mRNA expression. N=6, 8 fold-
change values calculated per animal, 48 fold-change values per group. OV>OR, 
P<0.0001. OV>SV, P<0.0001. OV>SR, P<0.0001. OR=SV, P>0.9999. SR=SV, 
P=0.9910. OR=SR, P=0.9883.  
[B] Neither OVA exposure nor treatment with RSV caused a significant change in the 
mRNA expression of CCL3. N=6, 8 fold-change values calculated per animal, 48 fold-
change values per group. OV=OR, P>0.9999. OV=SV, P=0.7346. OV=SR, P=0.4175. 
OR=SV, P=0.7225. SR=SV, P=0.9439. OR=SR, P=0.4060.  
[C] RSV prevented OVA-induced upregulation of CCL5 mRNA expression. N=6, 8 fold-
change values calculated per animal, 48 fold-change values per group. OV>OR, 
P<0.0001. OV>SV, P=0.0123. OV>SR, P=0.0003. OR=SV, P=0.0604. SR=SV, 
P=0.2252. OR=SR, P=0.9312. 
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CHAPTER 3. FUTURE DIRECTIONS 
 
3.1. Implications 
The goals of this pilot study were to determine if topical application of RSV: 1) 
has any effect on early IgE independent S1P elevation, MC activation, chemokine 
expression, cellular infiltration, as well as remodeling of skin tissue, and 2) affects the 
translocation of SphK1 to the cell membrane to reach its substrate. While this study is not 
yet complete, we now have enough evidence to conclude that topical application of RSV 
may serve as a prophylactic agent for AD. This conclusion serves as proof of our 
concept, enabling us to proceed with related work in the future. We intend to use our 
findings as standards for the evaluation of our upcoming research into effects of 
alternative dosing, similar compounds, and RSV as a treatment for AD. 
3.2. Ongoing Research 
 Although we have already found evidence to support several elements of our 
hypothesis, we are still working to complete the picture. Our outstanding objectives 
include determining: 1) how the effects of a lower dose of RSV differ from the dose we 
have already investigated, 2) whether RSV attenuates the enzymatic activity of SphK1 by 
preventing its translocation to the cell membrane, 3) if RSV affects local S1P levels, and 
4) if our ETOH vehicle causes any effects.  
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We have already completed another group of trials using a lower dose of RSV (1 
µg), but we have not yet been able to perform data analysis of these samples. Once we 
compare these results to those observed for the 2.5 µg treatment group, we will know if 
we should evaluate higher or lower doses in future trials.  
We are also currently working on localizing SphK1 at the subcellular level which 
will allow us to determine if RSV alters the translocation of SphK1 to the cell membrane, 
preventing it from reaching its substrate. Subcellular localization of SphK1 will be 
accomplished by staining of slides with immunofluorescent antibodies and collecting 
images via confocal microscopy. Slides will be deparaffinized and rehydrated before heat 
induced antigen retrieval. Phalloidin conjugated with AlexaFuor™ (488 nm) will be used 
for actin staining. Slides will then be treated with a rabbit anti-mouse anti-SphK1 
antibody or an isotype-matched negative control antibody. We will then use a goat anti-
rabbit Cy™ 3 (543nm) secondary antibody and mount slides using the 
VECTASHIELD™ DAPI paramount medium. A confocal microscope and software will 
be used to collect images to determine the cytoplasmic and membrane associated 
distributions of SphK1. We anticipate that there will be more membrane associated 
SphK1 in the MCs of animals exposed to OVA compared to vehicle controls, and that 
this increase is attenuated by RSV treatment. 
To strengthen our current results, we also plan to quantify local S1P via tissue 
lipidomic analysis to determine whether this mediator of the early inflammatory response 
is affected by RSV treatment. Tissue samples will be sent to the VCU Lipidomics Core 
for analysis using liquid chromatography-electrospray ionization-tandem mass 
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spectrometry, as previously reported.9 S1P quantities will be normalized to sample 
weight, averaged by group, and analyzed for significant differences.  
Prior to completing this pilot study, we will also perform another trial to ensure 
that our ETOH vehicle does not have any unanticipated effects. This trial will be 
performed using the previously described methods and will consist of a vehicle only 
group, a vehicle and OVA group, a saline only group, and a saline and OVA group. 
3.3. Investigation of the Dose-Response Relationship 
 As previously stated, the doses chosen for our initial evaluation of RSV were 
selected based on their theorized biological relevance and limited related research. In 
addition to these 2.5 µg and 1.0 µg doses, we plan to evaluate the effects of doses that are 
either higher or lower depending on the results of our 1.0 µg trial to obtain a clearer 
picture of RSV’s dose-response curve. 
3.4. Related Compounds 
 Due to scarce research into resveratrol and pterostilbene alone or in combination 
with NAM and NR cofactors with respect to chronic inflammatory diseases, this initial 
study provided us with the data we will need to determine if these other compounds can 
be at least as effective as resveratrol in the prevention of AD. 
3.5. Resveratrol as a Treatment for Atopic Dermatitis 
Since we have found that resveratrol can ameliorate several important effector 
mechanisms of AD pathogenesis, we will investigate whether it can reverse AD-
associated changes once they have already occurred using the same murine AD model. 
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